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A new term, ‘selective estrogen receptor modulator’
(SERM), has infiltrated the estrogen receptor (ER) litera-
ture lately [1]. It is nothing more than the reaffirmation of
an old fact, namely that different estrogens have different
effects, in different tissues. The major natural estrogens –
estradiol, estriol and estrone – bind ERs with differing
affinities, hence variations in their tissue distribution and
concentrations influence the extent of their estrogenic
effects. Studies with synthetic estrogens have focused on
antiestrogenic ligands, which bind ERs and interfere with
the actions of the natural estrogens. Tamoxifen is the
prototypical antiestrogen, and newer second-generation
antagonists, such as raloxifene, are in various stages of
clinical trials [2]. Both tamoxifen and raloxifene are
SERMs, because their antiestrogenic effects are
restricted to only certain tissues. Tamoxifen has been
used for more than 20 years to treat ER-positive breast
cancers [3]. It was first demonstrated to be effective in
advanced disease, later in adjuvant settings, and most
recently as a breast cancer preventant in women at high
risk. Thus, in various settings tamoxifen is an inhibitory
ER ligand in the breast, and this property explains both
its efficacy and its widespread use. 
The picture is not all rosy, however. True to its SERM
nature, tamoxifen is not antiestrogenic in all tissues. For
example, in the uterus tamoxifen is a potent estrogen,
where, like estradiol (when unopposed by progestins), it
induces epithelial hyperplasia and endometrial cancers
[4]. The excitement surrounding raloxifene stems from
the fact that, like tamoxifen, it is an antagonist in the
breast, but, unlike tamoxifen, it lacks estrogenic activity in
the uterus [2,5]. In summary, tamoxifen can be either an
agonist or an antagonist in normal tissues.
Unfortunately, the same duality of function operates in
malignant tissues, including breast cancers. Almost
without exception, breast cancers that initially respond
well to tamoxifen by growth cessation or regression even-
tually resume growing despite the continued presence of
the antagonist. How can this ‘acquired resistance’ be
explained? Most tamoxifen-resistant tumors continue to
express ER [6], suggesting that resistance is not simply
due to outgrowth of a nonresponsive, ER-negative sub-
population. Indeed, tamoxifen-resistant tumors remain
responsive to growth inhibition by pure antiestrogens (but
clinical data are sparse) and other hormonal therapies
[3,5]. Paradoxic reports of tumor stasis and even regression
after tamoxifen withdrawal in resistant patients [7] suggest
that in at least some resistant tumors the antagonist has
switched to an agonist. Thus, for several years the notion
has been advanced that the term ‘resistance’ inappropri-
ately describes such tumors, and that tamoxifen is not
simply inactive (as implied by the term ‘resistance), but,
instead, that it has switched to an agonist, and actively
stimulates tumor growth [8,9].
That the same ligand can have opposing transcriptional
and biologic effects has long been puzzling, but recent
advances in our understanding of the molecular biology of
steroid receptors has shed light on this paradox. We now
know that transcriptional regulation by liganded, DNA-
bound receptors is influenced by their association with
multiprotein activator or repressor complexes. Detailed
analyses of the identity and function of the constituent
‘coregulatory’ proteins in these complexes are being
carried out in many laboratories. They break down into
two classes – coactivators and corepressors – and involve
proteins with a variety of functions, including the follow-Breast Cancer Research    Vol 1 No 1 Horwitz
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ing: enzymes such as acetylases, deacetylases, methyl-
transferases, ubiquitin ligases, proteases, ATPases and
kinases; proteins with activator or repressor domains that
stabilize or destabilize protein–protein interactions; scaf-
folding proteins involved in the assembly of multiprotein
complexes; and even nonpeptide factors such as the
steroid receptor RNA activator [10,11].
What does this have to do with tamoxifen? It turns out
that the activity of the tamoxifen–ER complex can be
exquisitely modulated by the nature of the associated
coregulatory proteins. Binding of corepressors, such as the
silencing mediator for retinoid and thyroid receptors or
nuclear receptor corepressor, suppresses the partial agonist
activity of tamoxifen. At least one antagonist-specific coac-
tivator, the L7 switch protein for antagonist, enhances the
partial agonist activity of tamoxifen [9]. As a result of these
basic molecular studies, there is now intense interest in
correlating tamoxifen resistance in breast cancer with the
underexpression of corepressors or the overexpression of
coactivators. These proteins could clearly represent the
next targets for therapeutic interventions. Additionally,
although we have learned a great deal about steroid recep-
tor coregulatory proteins in recent years, most investiga-
tors believe that only a minor subset have been identified
to date. This is because the many subtle structural varia-
tions in the conformation of receptors that result from the
binding of different ligands yield multiple subtly different
targets on the receptor’s surface for the binding of a
variety of coregulators. It is this variability that can, in
part, explain the tissue specificity and paradoxic agonist
activity of ligands like tamoxifen.
The hunt is therefore also on to identify the large number
of endogenous coregulatory proteins that are probably
lurking in tissues, and, additionally, to synthesize their
pharmacologic equivalents with a view to manipulating the
functional direction of ligand–receptor complexes. In a
recent paper, Norris et al [12] described a novel method to
define an array of synthetic peptides that interact specifi-
cally with estradiol- or tamoxifen-occupied ER, and regu-
late their transcriptional activity. Several methods have
recently been developed to select members of random
peptide libraries based on their binding affinity to known
protein targets [13]. In the method of phage-display, a
library of phage, each displaying a different cloned peptide
sequence on its surface, is exposed to a plastic plate coated
with the target protein. Specifically bound phage are
eluted, the phage are amplified, and the process is
repeated for several rounds, after which the selected clones
of interest are isolated from the phage, the DNAs are
sequenced, and the peptides they encode are deduced.
Norris et al [12] used tamoxifen- or estradiol-occupied ER
as the target protein bound to the plate, and they ensured
that the receptors would be in the appropriate DNA-bound
structural conformation by precoating the plastic with
DNA containing estrogen response elements. The screen
led to the isolation of several, 15 amino acid peptides, rep-
resenting three major classes: a/b I, which interacts with
estradiol-occupied ER; a/b III or V, which interact with
tamoxifen-occupied ER; and a II, which interacts with ER
in the presence of either ligand, in the presence of a pure
antiestrogen, and even in the absence of ligand.
The  a/b I peptide SSNHQSSRLIELLSR interacts with
ER only in the presence of estradiol, and not in the presence
of SERMs like tamoxifen, raloxifene, GW7604, idoxifene,
nafoxidene or the pure antiestrogen ICI182,780. In the pres-
ence of agonists, it also interacts with the progesterone
receptor B-isoform, and glucocorticoid receptors. When
overexpressed,  a/b I and a II peptides reduce the transcrip-
tional activity of estradiol, whereas a/b III or V have no
effect, which is consistent with their inability to bind ER in
the presence of the agonist. On the other hand, peptides a/b
III or V are quite tamoxifen-specific for ER, but also bind
antagonist-occupied progesterone receptors. Six peptides of
the  a/b V class were isolated, that had the consensus
sequence (S/M)X(D/E)(W/F)(W/F)XXXL. a/b III or V, as
well as a II, inhibit the partial agonist effect of tamoxifen,
but do not alter transcription by estradiol-occupied ER. The
inhibitory activity of these synthetic peptides thus resem-
bles that of the natural corepressors SMRT and N-CoR [9].
It would be of interest to determine whether the complemen-
tary DNAs encoding these synthetic peptides could be used
as probes to isolate additional endogenous corepressors from
complementary DNA libraries. At present the list of known
corepressors is much smaller than that of known coactivators
[11], and it is unclear whether this discrepancy represents a
true cellular condition, or whether it is an artifact due to the
technical complexity of screening for corepressors. 
Norris et al [12] speculated that each class of peptides rec-
ognizes different protein contact sites on the ER protein;
contact sites that are generated specifically by the class of
ligand bound to the receptors. They postulated that these
contact sites could be targets for drug discovery. Analo-
gous suggestions have previously been made for the use of
corepressor or coactivator-occupied receptors to screen for
new ligands [9]. The studies of Norris et al [12], along with
those of others cited herein, indicate that we are at the
brink of important insights into the molecular mechanisms
by which ER and their ligands regulate hormone depen-
dence and resistance in breast cancers. These insights will
bring completely new approaches to treating these tumors,
and if their promise is confirmed they will allow us to
predict, and pehaps even prevent or reverse, development
of resistance. It is an exciting time to be studying the roles
of steroid hormones in breast cancer!
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